Literature DB >> 8348695

Attenuation of ecto-5'-nucleotidase activity and adenosine release in activated human polymorphonuclear leukocytes.

M Kitakaze1, M Hori, T Morioka, S Takashima, T Minamino, H Sato, M Inoue, T Kamada.   

Abstract

To examine whether activation of polymorphonuclear leukocytes attenuates release of adenosine through attenuation of their own ecto-5'-nucleotidase activity, human polymorphonuclear leukocytes were incubated with and without exposure to either N-formyl-methionyl-leucyl-phenylalanine (FMLP) or complement C5a. Ecto-5'-nucleotidase activity of polymorphonuclear leukocytes was attenuated by both FMLP and complement C5a (22.7 +/- 3.6 vs 9.7 +/- 2.6 nmol/min per 10(7) cells at 10(-6) M FMLP, P < .05; 21.5 +/- 2.2 vs 10.2 +/- 1.2 nmol/min per 10(7) cells at 5 x 10(-7) g/mL complement C5a, P < .001), whereas cytosolic 5'-nucleotidase activity was not affected by either FMLP or complement C5a. These reductions of ecto-5'-nucleotidase activity that were caused by both FMLP and complement C5a were dose and time dependent and were inhibited by superoxide dismutase. Desferrioxamine did not inhibit the decreases in ecto-5'-nucleotidase. In accordance with the decreases in ecto-5'-nucleotidase activity, release of adenosine was attenuated in the FMLP-pretreated and complement C5a-pretreated polymorphonuclear leukocytes, which were restored by concomitant administration of superoxide dismutase. The viability of FMLP-pretreated and complement C5a-pretreated polymorphonuclear leukocytes was markedly decreased compared with the untreated group after 60 minutes of hypoxia followed by 60 minutes of reoxygenation. Thus, we conclude that: (1) activation of polymorphonuclear leukocytes attenuates their own ecto-5'-nucleotidase activity and thereby reduces adenosine release, (2) reduction of ecto-5'-nucleotidase activity is attributable to generated superoxide anion in polymorphonuclear leukocytes, and (3) viability of polymorphonuclear leukocytes after hypoxia and reoxygenation largely depends on the extents of decreases in ecto-5'-nucleotidase activity.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8348695     DOI: 10.1161/01.res.73.3.524

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  7 in total

Review 1.  Regulation of neutrophil function by adenosine.

Authors:  Kathryn E Barletta; Klaus Ley; Borna Mehrad
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-04       Impact factor: 8.311

2.  Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5'-nucleotidase-mediated conversion of adenine nucleotides.

Authors:  L Morabito; M C Montesinos; D M Schreibman; L Balter; L F Thompson; R Resta; G Carlin; M A Huie; B N Cronstein
Journal:  J Clin Invest       Date:  1998-01-15       Impact factor: 14.808

Review 3.  The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets.

Authors:  Bertrand Allard; Maria Serena Longhi; Simon C Robson; John Stagg
Journal:  Immunol Rev       Date:  2017-03       Impact factor: 12.988

Review 4.  It is time to ask what adenosine can do for cardioprotection.

Authors:  M Kitakaze; M Hori
Journal:  Heart Vessels       Date:  1998       Impact factor: 2.037

5.  Adenosine promotes wound healing and mediates angiogenesis in response to tissue injury via occupancy of A(2A) receptors.

Authors:  M Carmen Montesinos; Avani Desai; Jiang-Fan Chen; Herman Yee; Michael A Schwarzschild; J Stephen Fink; Bruce N Cronstein
Journal:  Am J Pathol       Date:  2002-06       Impact factor: 4.307

Review 6.  Purinergic regulation of neutrophil chemotaxis.

Authors:  W G Junger
Journal:  Cell Mol Life Sci       Date:  2008-08       Impact factor: 9.261

7.  Neutrophil-derived 5'-adenosine monophosphate promotes endothelial barrier function via CD73-mediated conversion to adenosine and endothelial A2B receptor activation.

Authors:  P F Lennon; C T Taylor; G L Stahl; S P Colgan
Journal:  J Exp Med       Date:  1998-10-19       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.